Solta AI

EMDR is the most effective treatment for trauma and anxiety — recommended by the WHO, outperforming talk therapy and medication. But it costs $150–$300/session, requires 8+ sessions, and only 10% of therapists are trained in it. Waitlists stretch 6+ months. Meanwhile, 70% of people experience trauma in their lifetime, and most never connect their chronic pain, insomnia, or anxiety to unresolved traumatic memories. Solta AI makes EMDR accessible to anyone with a webcam.

First, our AI runs entirely client-side — real-time facial expression and voice emotion analysis via ONNX models in the browser. No API calls, no latency, no data leaving the device. This isn't an LLM wrapper. As we collect session data and integrate clinician feedback on emotional state labeling, we're building a fine-tuned model specifically calibrated for therapeutic contexts. No open-source model is trained on what a trauma response looks like during bilateral stimulation — that dataset doesn't exist yet, and we're creating it. Second, our adaptive bilateral stimulation system is patentable and we're pursuing patent protection. We're the only platform that dynamically adjusts therapeutic stimulation parameters based on real-time emotion detection — a compounding data flywheel where every session improves the models. Third, regulation is coming to this space, and we're positioning ourselves to shape it. We're building a clinical advisory board and engaging a regulatory consultant now so that when the FDA draws the line, we're already on the right side of it — and the barrier to entry rises for everyone behind us.

There are over 8 million Americans who meet clinical criteria for PTSD alone — and that doesn't include the broader population dealing with trauma-related anxiety, C-PTSD, or acute stress. Only about 50,000 therapists in the US are EMDR-trained, creating a fundamental supply-demand gap. Our near-term addressable market has two segments. On the consumer side: conservatively capturing 1% of the 8M underserved EMDR population gives us 80,000 users at $132/year, or roughly $10.5M in annual revenue. On the clinic side: 5% adoption among EMDR therapists — 2,500 clinics at $600/year — adds another $1.5M. That's a $12M near-term opportunity with zero international expansion and no new modalities. The broader opportunity expands significantly when you consider global trauma prevalence (approximately 70% of adults worldwide have experienced at least one traumatic event), expansion beyond EMDR into adjacent modalities, enterprise and payer channels, and the post-discharge outpatient model where we help prevent ER readmissions for trauma patients. The global behavioral health market exceeds $100B and is growing double digits annually. We're starting narrow — EMDR bilateral stimulation, direct-to-consumer and B2B2C — and expanding from a position of clinical credibility and proprietary data.

Phase 1: Prior to clinical validation we'll position ourselves as a wellness tool for nervous system regulation. Competitors will be Calm and Headspace. Phase 2: After clinical validation, we'll introduce messaging on therapy, EMDR, PTSD, trauma, etc. then our competitors are therapists charging $200/session + Virtual EMDR and Heal EMDR - who are not clinically validating and are not leveraging AI to adjust based on emotion.